JP2019522973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522973A5 JP2019522973A5 JP2018567062A JP2018567062A JP2019522973A5 JP 2019522973 A5 JP2019522973 A5 JP 2019522973A5 JP 2018567062 A JP2018567062 A JP 2018567062A JP 2018567062 A JP2018567062 A JP 2018567062A JP 2019522973 A5 JP2019522973 A5 JP 2019522973A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen recognition
- domain
- recognition domain
- receptor
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 45
- 102000036639 antigens Human genes 0.000 claims 45
- 108091007433 antigens Proteins 0.000 claims 45
- 210000004027 cell Anatomy 0.000 claims 34
- -1 NY-ES0-1 Proteins 0.000 claims 20
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 15
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 15
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 14
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 14
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 12
- 102000010956 Glypican Human genes 0.000 claims 12
- 108050001154 Glypican Proteins 0.000 claims 12
- 108050007237 Glypican-3 Proteins 0.000 claims 12
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 12
- 230000000139 costimulatory effect Effects 0.000 claims 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 11
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 9
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 9
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 9
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 9
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 9
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 9
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 9
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 9
- 102100035721 Syndecan-1 Human genes 0.000 claims 9
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 8
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 8
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 8
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 7
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 6
- 102100022749 Aminopeptidase N Human genes 0.000 claims 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 6
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 6
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 6
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 6
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 6
- 102100032999 Integrin beta-3 Human genes 0.000 claims 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 6
- 102100025136 Macrosialin Human genes 0.000 claims 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 6
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 5
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 5
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 4
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 4
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 4
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 4
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 claims 3
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100024304 Protachykinin-1 Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/039306 WO2016210293A1 (en) | 2015-06-25 | 2016-06-24 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| USPCT/US2016/039306 | 2016-06-24 | ||
| US201662369004P | 2016-07-29 | 2016-07-29 | |
| US62/369,004 | 2016-07-29 | ||
| PCT/US2016/068349 WO2017222593A1 (en) | 2016-06-24 | 2016-12-22 | Chimeric antigen receptors (cars), compositions and methods thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522973A JP2019522973A (ja) | 2019-08-22 |
| JP2019522973A5 true JP2019522973A5 (OSRAM) | 2020-02-06 |
| JP7114490B2 JP7114490B2 (ja) | 2022-08-08 |
Family
ID=60783276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567062A Active JP7114490B2 (ja) | 2016-06-24 | 2016-12-22 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20200283534A1 (OSRAM) |
| EP (2) | EP4353750A3 (OSRAM) |
| JP (1) | JP7114490B2 (OSRAM) |
| CN (1) | CN109562126A (OSRAM) |
| CA (1) | CA3029197A1 (OSRAM) |
| WO (1) | WO2017222593A1 (OSRAM) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE070137T2 (hu) | 2014-12-15 | 2025-05-28 | Univ California | CD19-re és CD20-ra érzékeny bispecifikus VAGY-kapu kiméra antigénreceptor |
| SG11201706236SA (en) | 2015-02-06 | 2017-08-30 | Nat Univ Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| US20220348633A1 (en) * | 2015-06-25 | 2022-11-03 | Icell Gene Therapeutics Llc | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF |
| CN115058395B (zh) * | 2015-06-25 | 2025-07-18 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| AU2016343805A1 (en) | 2015-10-30 | 2018-06-07 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| MX2018005315A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para el tratamiento del cancer. |
| US11384156B2 (en) * | 2016-07-25 | 2022-07-12 | The Nemours Foundation | Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases |
| EP3494132A4 (en) | 2016-08-03 | 2020-03-18 | Washington University | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| JP2019535262A (ja) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| CA3048648A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| US12473343B2 (en) | 2017-01-10 | 2025-11-18 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| AU2018229351B2 (en) | 2017-02-28 | 2024-01-04 | Vor Biopharma, Inc. | Compositions and methods for inhibition of lineage specific proteins |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| EP3609914A4 (en) | 2017-04-14 | 2021-04-14 | The General Hospital Corporation | CHIMERIC ANTIGEN RECEPTOR T-CELLS AGAINST TUMOR MICRO ENVIRONMENT |
| CN110753555A (zh) * | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP7356354B2 (ja) | 2017-05-12 | 2023-10-04 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用 |
| CN118853581A (zh) | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| CA3068841A1 (en) | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
| AU2018309735B2 (en) * | 2017-07-31 | 2025-03-13 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
| AU2018313939A1 (en) | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| CA3078963A1 (en) | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| JP7386796B2 (ja) | 2017-11-14 | 2023-11-27 | グリーン クロス ラボ セル コーポレーション | 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体 |
| KR20190065234A (ko) * | 2017-11-30 | 2019-06-11 | 그리폴스 다이어그노스틱 솔루션즈 인크. | 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질 |
| WO2019140127A2 (en) * | 2018-01-10 | 2019-07-18 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
| CN108314738B (zh) * | 2018-01-29 | 2020-09-08 | 山东兴瑞生物科技有限公司 | 一种共表达细胞因子il-21的双特异性嵌合抗原受体、质粒、cik细胞及mm病应用 |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| EP3752601A4 (en) * | 2018-02-15 | 2022-03-23 | Memorial Sloan-Kettering Cancer Center | FOXP3-TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| KR20250151559A (ko) * | 2018-03-15 | 2025-10-21 | 펀다멘탈 솔류션스 코포레이션 | 프로그램 가능한 면역세포 수용체 복합체 시스템 |
| EP3773657A4 (en) * | 2018-03-26 | 2021-12-08 | Altor Bioscience LLC | ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3773588A4 (en) * | 2018-04-09 | 2022-01-19 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASES |
| TWI723374B (zh) * | 2018-04-12 | 2021-04-01 | 美商凱特製藥公司 | 利用腫瘤微環境之特性之嵌合受體t細胞治療 |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| EP3784256A4 (en) * | 2018-04-27 | 2022-06-29 | Baylor College of Medicine | Car t cells with one or more interleukins |
| US12473342B2 (en) | 2018-04-27 | 2025-11-18 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis |
| CN110468105B (zh) * | 2018-05-09 | 2024-03-22 | 恺兴生命科技(上海)有限公司 | 表达il-18r结合蛋白的免疫效应细胞 |
| SG11202011080QA (en) | 2018-05-11 | 2020-12-30 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| EP3806871A4 (en) * | 2018-06-12 | 2022-02-23 | The Regents of the University of California | SINGLE-CHAIN BISPECIFIC CHEMICAL ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER |
| EP4365194A3 (en) | 2018-06-14 | 2024-07-24 | Regeneron Pharmaceuticals, Inc. | Cd79a chimeric antigen receptors |
| WO2019246593A2 (en) * | 2018-06-22 | 2019-12-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders |
| WO2020009868A1 (en) | 2018-07-03 | 2020-01-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-slamf7 chimeric antigen receptors |
| CN108864307A (zh) * | 2018-07-23 | 2018-11-23 | 北京多赢时代科技有限公司 | 信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用 |
| US20210079111A1 (en) * | 2018-08-04 | 2021-03-18 | AbCyte Therapeutics Inc. | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof |
| CN110862967A (zh) * | 2018-08-27 | 2020-03-06 | 天津天锐生物科技有限公司 | 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk |
| WO2020047164A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma, Inc | Genetically engineered hematopoietic stem cells and uses thereof |
| SG11202101930XA (en) * | 2018-08-31 | 2021-03-30 | Noile Immune Biotech Inc | Car-expressing t cells and car expression vector |
| JP7605735B2 (ja) * | 2018-09-05 | 2024-12-24 | ポセイダ セラピューティクス，インコーポレイティド | 同種異系細胞組成物およびその使用方法 |
| JP2022501067A (ja) * | 2018-09-26 | 2022-01-06 | 上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. | Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用 |
| CN110950965B (zh) * | 2018-09-26 | 2021-10-15 | 重庆精准生物技术有限公司 | 抗人cd123的嵌合抗原受体及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US20210338729A1 (en) * | 2018-10-12 | 2021-11-04 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF |
| US10993967B2 (en) * | 2018-10-17 | 2021-05-04 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| PE20211058A1 (es) * | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| US20200222462A1 (en) | 2018-11-30 | 2020-07-16 | Mustang Bio, Inc. | Methods of treatment using decitabine and a cd123-targeted therapy |
| US20220047636A1 (en) * | 2018-12-13 | 2022-02-17 | The General Hospital Corporation | Chimeric antigen receptors targeting cd79b and cd19 |
| CN113260703A (zh) * | 2018-12-24 | 2021-08-13 | 黄海东 | 突变的人2Ig-B7-H3蛋白编码基因、重组载体、包含其的宿主细胞、药物组合物及其应用 |
| JP2022524178A (ja) | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
| EP3917313A4 (en) * | 2019-02-01 | 2023-02-08 | Actinium Pharmaceuticals, Inc. | ANTI-CD45 MOLECULES AND DERIVATIVES THEREOF |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20220184128A1 (en) * | 2019-03-28 | 2022-06-16 | Korea Research Institute Of Bioscience And Biotechnology | Method for producing car gene-introduced nk cells and use thereof |
| US20220160771A1 (en) * | 2019-04-10 | 2022-05-26 | Iulia Diaconu | Flt3-specific chimeric antigen receptors and methods of using the same |
| CN110055281B (zh) * | 2019-04-25 | 2020-09-01 | 山东大学第二医院 | 一种用于制备car-t的慢病毒载体及其构建方法和应用 |
| JP2022531185A (ja) | 2019-04-30 | 2022-07-06 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法 |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| CN114025788A (zh) * | 2019-05-01 | 2022-02-08 | 朱诺治疗学股份有限公司 | 从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法 |
| EP3747904A1 (en) * | 2019-06-03 | 2020-12-09 | Universität Regensburg | Cd25-specific chimeric antigen receptors and their uses |
| EP3980453A4 (en) * | 2019-06-07 | 2023-07-05 | The Trustees of the University of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| BR112021025259A2 (pt) * | 2019-06-14 | 2022-03-15 | 2Seventy Bio Inc | Composições e métodos para tratar câncer |
| US20230181027A1 (en) * | 2019-06-28 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| CN112204135A (zh) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| EP3997129B1 (en) | 2019-07-11 | 2025-11-26 | Valkyr, Inc. | System and methods relating to chimeric autoantibody receptors |
| AU2020315213A1 (en) * | 2019-07-17 | 2022-02-03 | National University Of Singapore | Functional binders synthesized and secreted by immune cells |
| CN110452294B (zh) * | 2019-08-06 | 2020-08-07 | 复旦大学 | 五种铰链区及其嵌合抗原受体和免疫细胞 |
| WO2021041936A1 (en) * | 2019-08-28 | 2021-03-04 | Montefiore Medical Center | Cd25 chimeric antigen receptors and uses thereof |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| WO2021064718A1 (en) * | 2019-10-01 | 2021-04-08 | Case Western Reserve University | Targeting b cell activating factor receptor (baff-r) using ligand-based chimeric antigen receptor (car)-t cells |
| US12383581B2 (en) | 2019-10-11 | 2025-08-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia |
| TWI717880B (zh) | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| IL293552A (en) * | 2019-12-05 | 2022-08-01 | Vycellix Inc | Modulators of the immune escape mechanism for universal cell therapy |
| CN114761038A (zh) * | 2020-02-24 | 2022-07-15 | 凯斯西储大学 | 使用基于配体的嵌合抗原受体(car)-t细胞靶向b细胞激活因子受体(baff-r) |
| KR20220147109A (ko) * | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| WO2021207171A1 (en) * | 2020-04-06 | 2021-10-14 | St. Jude Children's Research Hospital, Inc. | B7-h3 chimeric antigen receptors |
| CN111411085A (zh) * | 2020-04-10 | 2020-07-14 | 格源致善(上海)生物科技有限公司 | 一种嵌合抗原受体t细胞及其应用 |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| WO2021223705A1 (en) * | 2020-05-06 | 2021-11-11 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| PE20230494A1 (es) | 2020-05-08 | 2023-03-23 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
| US20230338531A1 (en) * | 2020-08-20 | 2023-10-26 | City Of Hope | Compositions and uses of cd45 targeted chimeric antigen receptor modified t cells |
| US20230321242A1 (en) * | 2020-08-24 | 2023-10-12 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (car)-expressing cells recognizing cea |
| WO2022052913A1 (en) * | 2020-09-08 | 2022-03-17 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| CN116783283A (zh) * | 2020-11-13 | 2023-09-19 | Gpb科学有限公司 | 产生具有增加的核酸摄取的细胞群体的方法 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US20220195396A1 (en) * | 2020-12-03 | 2022-06-23 | Century Therapeutics, Inc. | Genetically Engineered Cells and Uses Thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| CN113234682B (zh) * | 2021-01-12 | 2023-02-21 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
| CN112778427B (zh) * | 2021-01-29 | 2022-03-15 | 武汉思安医疗技术有限公司 | 双特异性cs1-bcma car-t细胞及其应用 |
| US20220267423A1 (en) * | 2021-02-22 | 2022-08-25 | IgGenix, Inc. | Ige antibodies cross-reactive to allergens and tumor antigens |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| WO2022234976A1 (ko) * | 2021-05-04 | 2022-11-10 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR102671411B1 (ko) * | 2021-05-11 | 2024-06-04 | 진화섭 | Baff 세포외 도메인을 포함하는 키메릭 항원 수용체 및 이의 용도 |
| CN115340610A (zh) * | 2021-05-12 | 2022-11-15 | 珠海市丽珠单抗生物技术有限公司 | 双特异性car t细胞及其应用 |
| CN113501884B (zh) * | 2021-06-30 | 2022-03-22 | 徐州医科大学 | 靶向B7H3的全人源嵌合抗原受体、iNKT细胞及其用途 |
| CN113549158B (zh) * | 2021-07-19 | 2022-10-21 | 广州百暨基因科技有限公司 | 包含突变型il15以及嵌合抗原受体的融合蛋白 |
| US20230060292A1 (en) * | 2021-07-26 | 2023-03-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| US20250222102A1 (en) * | 2021-08-24 | 2025-07-10 | City Of Hope | Nk cells expressing il-15 and checkpoint inhibitors for the treatment of cancer |
| KR20230032557A (ko) | 2021-08-31 | 2023-03-07 | 주식회사 이뮤노로지컬디자이닝랩 | Baff 세포외 도메인을 포함하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
| AU2022347132A1 (en) * | 2021-09-16 | 2024-05-02 | Gt Biopharma, Inc. | B7-h3 targeting fusion proteins and methods of use thereof |
| WO2023091954A2 (en) * | 2021-11-19 | 2023-05-25 | The Trustees Of The University Of Pennsylvania | Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy |
| US20230210900A1 (en) * | 2022-01-04 | 2023-07-06 | Kyverna Therapeutics, Inc. | Methods for treating autoimmune diseases |
| EP4272754A1 (en) | 2022-05-04 | 2023-11-08 | Universitätsklinikum Hamburg-Eppendorf | Method for producing cells expressing a chimeric antigen receptor (car) |
| US20250295773A1 (en) * | 2022-05-10 | 2025-09-25 | Miltenyi Biotec B.V. & Co. KG | Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy |
| WO2024026455A2 (en) * | 2022-07-29 | 2024-02-01 | Shoreline Biosciences, Inc. | Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages |
| EP4487868A1 (en) | 2023-07-06 | 2025-01-08 | Universitätsklinikum Hamburg-Eppendorf | Modified nk cell expressing a chimeric antigen receptor |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025072372A1 (en) * | 2023-09-26 | 2025-04-03 | The General Hospital Corporation | Car-t cells expressing vegf binding proteins |
| CN117050195B (zh) * | 2023-10-13 | 2023-12-19 | 旭和（天津）医药科技有限公司 | 一种靶向baffr嵌合抗原受体、car-t细胞和应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030147865A1 (en) * | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| US20040265315A1 (en) | 2002-09-05 | 2004-12-30 | Christine Dingivan | Methods of preventing or treating T cell malignancies by administering CD2 antagonists |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005108415A2 (en) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
| US20050277587A1 (en) | 2004-06-10 | 2005-12-15 | Academia Sinica | CD7 as biomarker and therapeutic target for psoriasis |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| AU2007239095B2 (en) * | 2006-01-09 | 2012-05-03 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| CN101501498A (zh) | 2006-06-12 | 2009-08-05 | 森托科尔公司 | 根据rantes代表物水平检测il-16活性和对il-16活性的调节的方法 |
| BRPI0716680A2 (pt) | 2006-11-02 | 2013-09-24 | Daniel J Capon | "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo" |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| CA2735456C (en) * | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| ES2595364T3 (es) * | 2008-10-07 | 2016-12-29 | The Regents Of The University Of California | Producción de proteínas NELL recombinantes |
| US9206440B2 (en) | 2009-01-23 | 2015-12-08 | Roger Williams Hospital | Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same |
| EP2429584A4 (en) | 2009-05-13 | 2013-02-20 | Genzyme Corp | TREATMENT PROCEDURE AND COMPOSITIONS |
| EP2429583A4 (en) | 2009-05-13 | 2013-10-16 | Genzyme Corp | METHOD AND COMPOSITIONS FOR LUPUS TREATMENT |
| EP2325322A1 (en) | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Retroviral vector particles and methods for their generation and use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3693017A1 (en) | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| US8785190B2 (en) | 2011-04-06 | 2014-07-22 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
| KR101681818B1 (ko) | 2011-08-23 | 2016-12-01 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| EP2752200B1 (en) * | 2011-09-30 | 2023-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule inducing immune response to target antigen |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG11201404285VA (en) | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2953475B1 (en) * | 2013-02-06 | 2019-07-03 | Celgene Corporation | Modified t lymphocytes having improved specificity |
| KR102064230B1 (ko) | 2013-02-15 | 2020-01-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| US9745368B2 (en) * | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| BR112015028387B1 (pt) * | 2013-05-13 | 2023-04-11 | Cellectis | Receptor antigênico quimérico específico para cd19, polinucleotídeo, vetor de expressão, método in vitro para manipulação e uso de uma célula imune |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| JP6136650B2 (ja) * | 2013-06-28 | 2017-05-31 | ブラザー工業株式会社 | カートリッジ |
| EP3659622A1 (en) * | 2013-08-08 | 2020-06-03 | Cytune Pharma | Combined pharmaceutical composition |
| AU2014342020C1 (en) | 2013-10-31 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof |
| MY176522A (en) | 2013-11-04 | 2020-08-13 | Ichnos Sciences SA | Production of t cell retargeting hetero-dimeric immunoglobulins |
| MX373687B (es) | 2013-11-21 | 2020-07-07 | Ucl Business Ltd | Célula natural (nk) |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| EP3102236A4 (en) * | 2014-02-05 | 2017-08-30 | The University of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| PT3105317T (pt) | 2014-02-14 | 2019-02-27 | Cellectis | Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas |
| AU2015220762B2 (en) * | 2014-02-21 | 2019-05-02 | Cellectis | Method for in situ inhibition of regulatory T cells |
| KR102463529B1 (ko) * | 2014-04-10 | 2022-11-07 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 약물 관련 트랜스진 발현 |
| US10301370B2 (en) * | 2014-05-02 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor T cells |
| US10604740B2 (en) | 2014-05-14 | 2020-03-31 | Carsgen Therapeutics Limited | Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| ES2791248T3 (es) * | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| RU2764074C2 (ru) | 2014-08-28 | 2022-01-13 | Байоатла, Ллк | Условно активные химерные антигенные рецепторы для модифицированных т-клеток |
| US10577417B2 (en) * | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3215535A2 (en) * | 2014-11-05 | 2017-09-13 | Board of Regents, The University of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| CA3224507A1 (en) | 2014-12-24 | 2016-06-30 | Autolus Limited | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
| CN115058395B (zh) * | 2015-06-25 | 2025-07-18 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| IL296410A (en) * | 2015-11-27 | 2022-11-01 | Cartherics Pty Ltd | Genetically modified stem cells and their uses |
| WO2017149515A1 (en) * | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| GB201610512D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| WO2018067992A1 (en) * | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
-
2016
- 2016-12-22 WO PCT/US2016/068349 patent/WO2017222593A1/en not_active Ceased
- 2016-12-22 JP JP2018567062A patent/JP7114490B2/ja active Active
- 2016-12-22 EP EP23220747.2A patent/EP4353750A3/en not_active Withdrawn
- 2016-12-22 EP EP16906492.0A patent/EP3474867A4/en active Pending
- 2016-12-22 CN CN201680087034.6A patent/CN109562126A/zh active Pending
- 2016-12-22 US US16/312,769 patent/US20200283534A1/en not_active Abandoned
- 2016-12-22 CA CA3029197A patent/CA3029197A1/en active Pending
-
2017
- 2017-06-21 US US15/538,620 patent/US11820819B2/en active Active
-
2022
- 2022-08-01 US US17/878,339 patent/US20230340113A1/en active Pending
-
2023
- 2023-10-13 US US18/379,708 patent/US20240141041A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522973A5 (OSRAM) | ||
| JP2018518974A5 (OSRAM) | ||
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Birkholz et al. | Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer | |
| Li et al. | Preclinical and clinical studies of CAR-NK-cell therapies for malignancies | |
| Benmebarek et al. | Killing mechanisms of chimeric antigen receptor (CAR) T cells | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| JP2017513470A5 (OSRAM) | ||
| Morgan et al. | Engineering CAR-T cells for improved function against solid tumors | |
| JP2020074776A5 (OSRAM) | ||
| JP2019528769A5 (OSRAM) | ||
| AU2014407540C1 (en) | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation | |
| JP2021019589A5 (OSRAM) | ||
| CN105175544B (zh) | 一种抗pd-1人源化单克隆抗体及其应用 | |
| JP2017515464A5 (OSRAM) | ||
| JP2022159548A5 (OSRAM) | ||
| JP2018506981A5 (OSRAM) | ||
| JP2019500012A5 (OSRAM) | ||
| JP2020517259A5 (OSRAM) | ||
| JP2020513828A5 (OSRAM) | ||
| JP2017522862A5 (OSRAM) | ||
| JP2018522567A5 (OSRAM) | ||
| JP2017537627A5 (OSRAM) | ||
| JP2018517415A5 (OSRAM) | ||
| JP2018519356A5 (OSRAM) |